Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This notice of funding opportunity (NOFO) will support research to improve our understanding of psychedelic drug mechanisms in the context of substance use disorders (SUDs). This NOFO will also support the design and synthesis of chemical biology tools and probes to aid basic research on psychedelics and their translational pharmacology. 

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material.

Companion FOAs:

 

RFA-DA-24-024 , R61R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
RFA-DA-24-029 , R61R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II

Deadlines:

  • Letter of Intent Due Date(s): October 2, 2023

  • Application Due Date: November 02, 2023

RFA-DA-24-028 Expiration Date November 03, 2023

Agency Website

Amount

$1,750,000

Amount Description

Application budgets are limited to $350,000 direct costs per year and need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

November 2, 2023